Bioenvision to Present At Wall Street Analyst Forum On Monday, November 11, 2002.Business Editors NEW YORK--(BUSINESS WIRE)--Nov. 8, 2002 Bioenvision, Inc. (OTCBB OTCBB See OTC Bulletin Board (OTCBB). :BIOV.OB), a leading biotechnology company focused on the commercialization of novel compounds for cancer treatment, will be presenting at the Wall Street Analyst Forum on Monday at 9:00 a.m. Eastern Standard Time in the Sutton Suite at the Roosevelt Hotel
New York City City (pop., 2000: 8,008,278), southeastern New York, at the mouth of the Hudson River. The largest city in the U.S. . Christopher B. Wood, M.D., Chairman and Chief Executive Officer of Bioenvision will be presenting a corporate overview and an update of the product pipeline. A live web simulcast can be accessed from the home page at Bioenvision's website at www.Bioenvision.com. The slide presentation with audio replay will be archived on Bioenvision's website for 15 days. Analysts and portfolio managers who wish to attend the presentation this Monday may contact the Wall Street Analyst Forum directly at (802) 253-7596 to request additional information. About Bioenvision Bioenvision's primary focus is the acquisition, development and distribution of compounds and technologies for the treatment of cancer. Bioenvision has a broad pipeline of products for the treatment of cancer, including: clofarabine (in co-development with ILEX Ilex a bush bearing berries containing saponins; cause vomiting, diarrhea. Called also holly. Oncology, Inc.); Modrenal(R) (for which Bioenvision has obtained regulatory approval for marketing in the United Kingdom for the treatment of post-menopausal breast cancer); and other products in clinical trials. Bioenvision is also developing anti-infective technologies, including the OLIGON technology, an advanced biomaterial biomaterial /bio·ma·te·ri·al/ (bi?o-mah-ter´e-al) a synthetic dressing with selective barrier properties, used in the treatment of burns; it consists of a liquid solvent (polyethylene glycol-400) and a powdered polymer. that has been approved for certain indications in the U.S. For more information on Bioenvision please visit our Web site at www.bioenvision.com. Certain statements contained herein are "forward-looking" statements (as such term is defined in the Private Securities Litigation Reform Act The Private Securities Litigation Reform Act of 1995 (PSLRA) implemented several significant substantive changes affecting certain cases brought under the federal securities laws, including changes related to pleading, discovery, liability, class representation and awards fees and of 1995). Because these statements include risks and uncertainties, actual results may differ materially from those expressed or implied by such forward-looking statements forward-looking statement A projected financial statement based on management expectations. A forward-looking statement involves risks with regard to the accuracy of assumptions underlying the projections. . Specifically, factors that could cause actual results to differ materially from those expressed or implied by such forward-looking statements include, but are not limited to: risks associated with preclinical and clinical developments in the biopharmaceutical industry in general and in Bioenvision's compounds under development in particular; the potential failure of Bioenvision's compounds under development to prove safe and effective for treatment of disease; uncertainties inherent in the early stage of Bioenvision's compounds under development; failure to successfully implement or complete clinical trials; failure to receive marketing clearance from regulatory agencies regulatory agency Independent government commission charged by the legislature with setting and enforcing standards for specific industries in the private sector. The concept was invented by the U.S. for our compounds under development; acquisitions, divestitures, mergers, licenses or strategic initiatives that change Bioenvision's business, structure or projections; the development of competing products; uncertainties related to Bioenvision's dependence on third parties and partners; and those risks described in Bioenvision's filings with the SEC. Bioenvision disclaims any obligation to update these forward-looking statements. |
|
||||||||||||||
Printer friendly
Cite/link
Email
Feedback
Reader Opinion